


# Reference Data

(Consolidated Financial Results for Q1 FY2016)



Daiichi-Sankyo

July 29, 2016

Daiichi Sankyo Co., Ltd.

<http://www.daiichisankyo.com>

# Contents

1.	Consolidated Statement of Profit or Loss	P1
2.	Revenue of Global Products	P2
3.	Revenue by Business Units and Products	P3
4.	Consolidated Statement of Financial Position	P6
5.	Consolidated Statement of Cash Flows	P8
6.	Number of Employees	P9
7.	Capital Expenditure and Depreciation and Amortization	P9
8.	Summary of Product Outlines	P10
9.	Quarterly Data	P11
10.	Historical Data	P16
11.	Major R&D Pipeline (Innovative pharmaceuticals)	P20

# 1. Consolidated Statement of Profit or Loss

JPY Bn	FY2015 Q1		FY2016 Q1					FY2016			
	to revenue	Results	to revenue	Results	(vs. Forecast (%))	YoY	YoY (%)	to revenue	Forecast	YoY	YoY (%)
<b>Revenue</b>	100.0%	238.4	100.0%	241.0	(26.2%)	2.6	+1.1%	100.0%	920.0	-66.4	-6.7%
Cost of sales	31.0%	74.0	32.2%	77.6	(24.3%)	3.7	+4.9%	34.8%	320.0	1.4	+0.4%
(excl. Special items)	32.0%	76.3	32.2%	77.6		1.3	+1.7%				
(Special items)	-1.0%	-2.4	-	-		2.4	-				
<b>Gross Profit</b>	69.0%	164.5	67.8%	163.4	(27.2%)	-1.1	-0.7%	65.2%	600.0	-67.8	-10.2%
SG&A expenses	30.0%	71.6	28.8%	69.5	(22.4%)	-2.1	-3.0%	33.7%	310.0	-18.8	-5.7%
(excl. Special items)	31.7%	75.6	28.8%	69.5		-6.1	-8.0%				
(Special items)	-1.6%	-3.9	-	-		3.9	-				
R&D expenses	18.3%	43.7	19.3%	46.6	(24.5%)	2.9	+6.7%	20.7%	190.0	-18.7	-8.9%
(excl. Special items)	18.3%	43.7	19.3%	46.6		2.9	+6.7%				
(Special items)	-	-	-	-		-	-				
<b>Operating Profit</b>	20.6%	49.1	19.6%	47.3	(47.3%)	-1.9	-3.8%	10.9%	100.0	-30.4	-23.3%
(Operating Profit before Special items)	18.0%	42.9	19.6%	47.3		4.4	+10.3%				
Financial income/expenses		-3.7		-1.9		1.9					
Share of profit or loss of investments accounted for using the equity method		-0.2		-0.2		-0.0					
<b>Profit before tax</b>	19.0%	45.2	18.8%	45.2	(45.2%)	0.0	+0.0%	10.9%	100.0	-22.4	-18.3%
Income taxes		11.1		15.1		4.0	+36.1%				
<b>Profit for the year</b>	14.3%	34.1	12.5%	30.1		-4.0	-11.7%				
<b>Profit attributable to owners of the Company</b>	14.7%	34.9	12.7%	30.6	(47.1%)	-4.3	-12.4%	7.1%	65.0	-17.3	-21.0%
Tax rate		24.6%		33.4%							
Overseas sales ratio		46.8%		42.0%							
Currency Rate (Average)											
USD/JPY		121.37		108.25					110.00		
EUR/JPY		134.16		122.17					125.00		

Forex impact: -12.6  
(USD: -7.8, EUR: -2.0, ASCA: -2.8)

Forex impact: -1.3  
(ASCA: -1.0)

Forex impact: -3.6  
(USD: -1.9, EUR: -0.8, ASCA: -0.9)

Forex impact: -2.4  
(USD: -2.1, EUR: -0.2)

Forex impact: -5.4  
(USD: -3.7, EUR: -0.8, ASCA: -0.9)

FY2015:  
Expenses relating to sale of Sun  
Pharma shares etc.  
FY2016:  
Increase in forex loss

Decrease in R&D tax credit

### Special items

	FY2015 Q1	FY2016 Q1
Cost of Sales	Gain on sales of subsidiary -2.4	-
SG&A expenses	Gain on sales of fixed assets -3.9	-
R&D expenses	-	-
<b>Total</b>	<b>-6.3</b>	<b>-</b>

### Annual impact of one yen change

	Forecast	
	USD	EUR
Revenue	2.0 JPY Bn	0.6 JPY Bn
Operating Profit	minor	minor

\*At the time of disclosure of this report, the audit/review procedures for financial statements are in progress in accordance with the Financial Instruments and Exchange Act.

\*Special items : Items having a transitory and material impact on operating profit are defined as "Special items". Specifically, gains and losses related to: sale of fixed assets, restructuring, impairment, litigation, etc. amounting to 1 billion JPY or more are defined as "Special items".

## 2. Revenue of Global Products

JPY Bn	FY2015 Q1		FY2016 Q1				FY2016		
	Results		Results	(vs. Forecast (%))	YoY	YoY (%)	Forecast	YoY	YoY (%)
<b>Olmesartan</b> antihypertensive agent	<b>75.6</b>		<b>65.7</b>	<b>(31.3%)</b>	<b>-10.0</b>	<b>-13.2%</b>	<b>210.0</b>	<b>-74.1</b>	<b>-26.1%</b>
Olmetec (JPN)	18.5		18.3	(26.8%)	-0.2	-1.1%	68.0	-5.9	-7.9%
Rezaltas (JPN)	4.6		4.7	(24.5%)	0.0	+1.0%	19.0	0.8	+4.6%
Benicar/Benicar HCT (US)	19.8		17.3	(41.2%)	-2.5	-12.7%	42.0	-37.5	-47.1%
Azor (US)	5.8		3.3	(33.5%)	-2.5	-42.7%	10.0	-9.7	-49.3%
Tribenzor (US)	3.1		2.5	(42.0%)	-0.6	-19.0%	6.0	-6.4	-51.7%
Olmetec/Olmetec Plus (EU)	8.9		7.7	(32.2%)	-1.2	-13.0%	24.0	-8.8	-26.9%
Sevikar (EU)	4.5		3.6	(27.6%)	-0.9	-19.7%	13.0	-3.5	-21.0%
Sevikar HCT (EU)	2.5		2.7	(29.5%)	0.2	+8.4%	9.0	-0.6	-6.5%
Other subsidiaries, export, etc	7.9		5.6	(29.5%)	-2.3	-29.2%	19.0	-2.6	-12.0%
<b>Prasugrel</b> antiplatelet agent	<b>7.8</b>		<b>10.9</b>	<b>-</b>	<b>3.1</b>	<b>+39.3%</b>	<b>not disclosed</b>	<b>-</b>	<b>-</b>
Effient alliance revenue (US)	5.2		6.0	-	0.8	+14.7%	not disclosed	-	-
Efient (EU)	1.1		2.3	-	1.2	+104.5%	not disclosed	-	-
Efient (JPN)	1.2		2.5	(30.9%)	1.3	+113.1%	8.0	3.1	+63.3%
Other subsidiaries, export, etc	0.3		0.2	-	-0.2	-53.6%	not disclosed	-	-
<b>Edoxaban</b> anticoagulant agent	<b>1.8</b>		<b>7.3</b>	<b>(20.2%)</b>	<b>5.5</b>	<b>+298.1%</b>	<b>36.3</b>	<b>21.3</b>	<b>+141.6%</b>
Lixiana (JPN)	2.1		5.5	(22.0%)	3.4	+160.3%	25.0	12.0	+92.6%
Savaysa (US)	-0.3		0.3	(14.9%)	0.6	-	2.0	1.6	+344.5%
Lixiana (EU)	0.0		1.4	(16.1%)	1.4	-	9.0	7.5	+482.3%
Other subsidiaries	-		0.1	(24.5%)	0.1	-	0.3	0.3	+550.5%

### 3. Revenue by Business Units and Products (1)

JPY Bn			FY2015 Q1		FY2016 Q1				FY2016		
			Results	Results	(vs. Forecast (%))	YoY	YoY (%)	Forecast	YoY	YoY (%)	
<b>Japan</b>			<b>114.2</b>	<b>123.4</b>	<b>(24.9%)</b>	<b>9.2</b>	<b>+8.0%</b>	<b>496.0</b>	<b>1.3</b>	<b>+0.3%</b>	
	Nexium	ulcer treatment	19.1	21.0	(26.3%)	1.9	+10.2%	80.0	-2.4	-2.9%	
	Olmetec	antihypertensive agent	18.5	18.3	(26.8%)	-0.2	-1.1%	68.0	-5.9	-7.9%	
	Memary	Alzheimer's disease treatment	10.2	12.1	(23.8%)	1.9	+18.4%	51.0	8.6	+20.2%	
	Loxonin	anti-inflammatory analgesic	12.6	10.3	(27.8%)	-2.3	-18.0%	37.0	-11.1	-23.1%	
	Tenelia	type 2 diabetes mellitus inhibitor	2.4	6.7	(23.8%)	4.3	+181.1%	28.0	11.5	+69.3%	
	Lixiana	anticoagulant agent	2.1	5.5	(22.0%)	3.4	+160.3%	25.0	12.0	+92.6%	
	Rezaltas	antihypertensive agent	4.6	4.7	(24.5%)	0.0	+1.0%	19.0	0.8	+4.6%	
	Pralia	treatment for osteoporosis	2.6	4.1	(25.7%)	1.6	+61.2%	16.0	3.5	+28.5%	
	Ranmark	treatment for bone complications caused by bone metastases from tumors	2.9	3.4	(25.9%)	0.5	+16.6%	13.0	0.6	+4.9%	
	Inavir	anti-influenza treatment	0.0	0.6	(4.2%)	0.5	-	13.0	-1.0	-7.3%	
	Cravit	synthetic antibacterial agent	4.6	3.8	(28.9%)	-0.9	-18.7%	13.0	-5.4	-29.2%	
	Omnipaque	contrast medium	4.2	3.7	(30.5%)	-0.6	-13.3%	12.0	-4.9	-28.8%	
	Urief	treatment for dysuria	2.9	3.0	(27.3%)	0.1	+5.1%	11.0	-0.8	-7.0%	
	Artist	treatment for hypertension, angina pectoris and chronic heart failure	4.1	3.1	(28.3%)	-1.0	-24.1%	11.0	-4.1	-27.0%	
	Mevalotin	antihyperlipidemic agent	3.6	2.9	(29.3%)	-0.6	-18.0%	10.0	-3.4	-25.6%	
	Efient	antiplatelet agent	1.2	2.5	(30.9%)	1.3	+113.1%	8.0	3.1	+63.3%	
	Daiichi Sankyo Espha products		4.3	5.2	-	0.9	+22.1%	not disclosed	-	-	
	Vaccines business		6.4	6.6	-	0.3	+4.2%	not disclosed	-	-	
<b>Daiichi Sankyo Healthcare (OTC)</b>			<b>10.8</b>	<b>14.8</b>	<b>(24.7%)</b>	<b>4.0</b>	<b>+37.0%</b>	<b>60.0</b>	<b>6.6</b>	<b>+12.4%</b>	

### 3. Revenue by Business Units and Products (2)

JPY Bn

	FY2015 Q1	FY2016 Q1				FY2016		
	Results	Results	(vs. Forecast (%))	YoY	YoY (%)	Forecast	YoY	YoY (%)
<b>Daiichi Sankyo, Inc. (US)</b>	<b>48.0</b>	<b>40.7</b>	<b>(33.1%)</b>	<b>-7.3</b>	<b>-15.2%</b>	<b>123.0</b>	<b>-62.1</b>	<b>-33.5%</b>
Olmesartan antihypertensive agent	28.8	23.2	(40.0%)	-5.6	-19.5%	58.0	-53.6	-48.0%
Benicar/Benicar HCT	19.8	17.3	(41.2%)	-2.5	-12.7%	42.0	-37.5	-47.1%
Azor	5.8	3.3	(33.5%)	-2.5	-42.7%	10.0	-9.7	-49.3%
Tribenzor	3.1	2.5	(42.0%)	-0.6	-19.0%	6.0	-6.4	-51.7%
Welchol hypercholesterolemia treatment/ type 2 diabetes mellitus inhibitor	13.5	10.0	(27.0%)	-3.6	-26.3%	37.0	-11.4	-23.5%
Effient antiplatelet agent	5.2	6.0	-	0.8	+14.7%	not disclosed	-	-
Savaysa anticoagulant agent	-0.3	0.3	(14.9%)	0.6	-	2.0	1.6	+344.5%
Movantik opioid-induced constipation treatment	0.2	0.9	-	0.7	+431.4%	not disclosed	-	-
<b>Luitpold Pharmaceuticals, Inc. (US)</b>	<b>21.5</b>	<b>22.0</b>	<b>(23.9%)</b>	<b>0.4</b>	<b>+2.0%</b>	<b>92.0</b>	<b>1.0</b>	<b>+1.1%</b>
Venofer treatment for iron deficiency anemia	9.1	7.4	(29.5%)	-1.7	-18.8%	25.0	-6.2	-19.9%
Injectafer treatment for iron deficiency anemia	3.9	5.9	(21.9%)	2.0	+52.4%	27.0	8.4	+44.9%
<b>Daiichi Sankyo Europe GmbH</b>	<b>20.2</b>	<b>20.4</b>	<b>(27.6%)</b>	<b>0.2</b>	<b>+1.2%</b>	<b>74.0</b>	<b>-3.8</b>	<b>-4.9%</b>
Olmesartan antihypertensive agent	15.8	14.0	(30.4%)	-1.8	-11.6%	46.0	-12.9	-21.9%
Olmetec/Olmetec Plus	8.9	7.7	(32.2%)	-1.2	-13.0%	24.0	-8.8	-26.9%
Sevikar	4.5	3.6	(27.6%)	-0.9	-19.7%	13.0	-3.5	-21.0%
Sevikar HCT	2.5	2.7	(29.5%)	0.2	+8.4%	9.0	-0.6	-6.5%
Effient antiplatelet agent	1.1	2.3	-	1.2	+104.5%	not disclosed	-	-
Lixiana anticoagulant agent	0.0	1.4	(16.1%)	1.4	-	9.0	7.5	+482.3%
<b>Asia, South and Central America (ASCA)</b>	<b>21.4</b>	<b>17.7</b>	<b>(25.0%)</b>	<b>-3.7</b>	<b>-17.2%</b>	<b>71.0</b>	<b>-4.3</b>	<b>-5.8%</b>
Daiichi Sankyo China	7.9	8.2	-	0.3	+4.2%	not disclosed	-	-
Daiichi Sankyo Taiwan	1.4	1.3	-	-0.1	-7.9%	not disclosed	-	-
Daiichi Sankyo Korea	2.4	2.1	-	-0.3	-12.7%	not disclosed	-	-
Daiichi Sankyo Thailand	0.8	0.6	-	-0.2	-28.8%	not disclosed	-	-
Daiichi Sankyo Brasil Farmacêutica	2.6	2.0	-	-0.6	-22.6%	not disclosed	-	-
Daiichi Sankyo Venezuela	3.1	0.0	-	-3.1	-99.7%	not disclosed	-	-

### 3. Revenue by Business Units and Products (3)

#### [Reference] Revenue in Local Currency

USD Mn

	FY2015 Q1	FY2016 Q1				FY2016		
	Results	Results	(vs. Forecast (%))	YoY	YoY (%)	Forecast	YoY	YoY (%)
<b>Daiichi Sankyo, Inc. (US)</b>	<b>396</b>	<b>376</b>	<b>(33.6%)</b>	<b>-19</b>	<b>-4.9%</b>	<b>1,118</b>	<b>-422</b>	<b>-27.4%</b>
Olmesartan antihypertensive agent	237	214	(40.6%)	-23	-9.7%	527	-402	-43.2%
Benicar/Benicar HCT	163	160	(41.9%)	-4	-2.2%	382	-280	-42.3%
Azor	48	31	(34.0%)	-17	-35.8%	91	-73	-44.7%
Tribenzor	26	23	(42.7%)	-2	-9.2%	55	-49	-47.2%
Welchol hypercholesterolemia treatment/ type 2 diabetes mellitus inhibitor	112	92	(27.4%)	-19	-17.4%	336	-66	-16.5%
Effient antiplatelet agent	43	55	-	12	+28.6%	not disclosed	-	-
Savaysa anticoagulant agent	-2	3	(15.2%)	5	-	18	14	+385.4%
Movantik opioid-induced constipation treatment	1	8	-	7	+495.8%	not disclosed	-	-

USD Mn

<b>Luitpold Pharmaceuticals, Inc. (US)</b>	<b>177</b>	<b>203</b>	<b>(24.3%)</b>	<b>26</b>	<b>+14.4%</b>	<b>836</b>	<b>79</b>	<b>+10.4%</b>
Venofer treatment for iron deficiency anemia	75	68	(30.0%)	-7	-8.9%	227	-33	-12.5%
Injectafer treatment for iron deficiency anemia	32	55	(22.3%)	23	+70.9%	245	90	+58.2%

EUR Mn

<b>Daiichi Sankyo Europe GmbH</b>	<b>151</b>	<b>167</b>	<b>(28.3%)</b>	<b>17</b>	<b>+11.1%</b>	<b>592</b>	<b>5</b>	<b>+0.9%</b>
Olmesartan antihypertensive agent	118	114	(31.1%)	-3	-2.9%	368	-76	-17.2%
Olmetec/Olmetec Plus	66	63	(33.0%)	-3	-4.4%	192	-56	-22.4%
Sevikar	33	29	(28.2%)	-4	-11.8%	104	-20	-16.3%
Sevikar HCT	18	22	(30.2%)	3	+19.0%	72	-1	-0.8%
Effient antiplatelet agent	8	19	-	10	+124.5%	not disclosed	-	-
Lixiana anticoagulant agent	0	12	(16.5%)	12	-	72	60	+517.6%

#### 4. Consolidated Statement of Financial Position

<Assets>

JPY Bn

	Mar. 2016	Jun. 2016	vs. Mar. 2016
Assets			
Current assets			
Cash and cash equivalents	222.2	258.9	36.7
Trade and other receivables	248.8	246.3	-2.5
Other financial assets	493.8	419.8	-73.9
Inventories	144.3	144.1	-0.2
Other current assets	15.2	16.6	1.4
Subtotal	1,124.2	1,085.7	-38.5
Assets held for sale	1.1	1.0	-0.0
<b>Total current assets</b>	<b>1,125.3</b>	<b>1,086.7</b>	<b>-38.5</b>
Non-current assets			
Property, plant and equipment	250.2	242.9	-7.3
Goodwill	78.7	73.8	-4.9
Intangible assets	210.4	206.5	-3.9
Investments accounted for using the equity method	1.2	1.0	-0.2
Other financial assets	168.2	158.1	-10.1
Deferred tax assets	55.7	62.7	7.0
Other non-current assets	10.9	10.7	-0.2
<b>Total non-current assets</b>	<b>775.3</b>	<b>755.7</b>	<b>-19.5</b>
<b>Total assets</b>	<b>1,900.5</b>	<b>1,842.4</b>	<b>-58.1</b>
* Liquidity on hand	714.7	677.8	-36.9
Debt with interest	203.6	203.0	-0.6
Net Cash	511.1	474.8	-36.3

Dividends paid, Forex loss

Forex loss

Forex loss

Acquisition +9.8, Amortization -3.6,  
Forex loss -10.0

Evaluation loss -10.5



## &lt;Liabilities and equity&gt;

JPY Bn

	Mar. 2016	Jun. 2016	vs. Mar. 2016
<b>Liabilities</b>			
Current liabilities			
Trade and other payables	241.8	231.2	-10.6
Bonds and borrowings	20.0	20.0	-
Other financial liabilities	0.8	0.6	-0.2
Income taxes payable	53.9	64.3	10.3
Provisions	28.3	22.9	-5.4
Other current liabilities	34.8	36.4	1.6
<b>Total current liabilities</b>	<b>379.7</b>	<b>375.4</b>	<b>-4.3</b>
Non-current liabilities			
Bonds and borrowings	181.0	181.0	-
Other financial liabilities	9.1	9.0	-0.1
Post employment benefit liabilities	14.0	14.1	0.1
Provisions	12.3	11.9	-0.3
Deferred tax liabilities	33.7	30.7	-3.0
Other non-current liabilities	37.2	33.5	-3.6
<b>Total non-current liabilities</b>	<b>287.3</b>	<b>280.3</b>	<b>-7.0</b>
<b>Total liabilities</b>	<b>667.0</b>	<b>655.6</b>	<b>-11.4</b>
<b>Equity</b>			
Equity attributable to owners of the Company			
Share capital	50.0	50.0	-
Capital surplus	103.9	103.8	-0.1
Treasury shares	-64.2	-71.5	-7.3
Other components of equity	146.7	98.5	-48.3
Retained earnings	994.9	1,005.0	10.1
<b>Total equity attributable to owners of the Company</b>	<b>1,231.4</b>	<b>1,185.8</b>	<b>-45.6</b>
Non-controlling interests			
Non-controlling interests	2.1	1.0	-1.1
<b>Total equity</b>	<b>1,233.5</b>	<b>1,186.8</b>	<b>-46.7</b>
<b>Total liabilities and equity</b>	<b>1,900.5</b>	<b>1,842.4</b>	<b>-58.1</b>

Acquisition -7.3 (3 million shares)

Forex loss

Profit for the period +30.6,  
Dividends -20.5

## 5. Consolidated Statement of Cash Flows

JPY Bn

	FY2015 Q1	FY2016 Q1	YoY
Cash flows from operating activities			
Profit before tax	45.2	45.2	0.0
Depreciation and amortization	10.6	10.9	0.3
(Increase) decrease in receivables and payables	-17.0	-10.3	6.8
Other, net	-2.6	-6.3	-3.7
Income taxes paid	-10.4	-6.5	3.9
<b>Net cash flows from operating activities</b>	<b>25.7</b>	<b>33.0</b>	<b>7.2</b>
Cash flows from investing activities			
Net (increase) decrease in time deposits and securities	-277.2	58.0	335.3
(Acquisition of) proceeds from sales of fixed assets	-26.9	-6.9	20.0
Proceeds from sale of subsidiary	7.0	-	-7.0
Net (increase) decrease in investment securities	373.8	-0.8	-374.6
Other, net	-3.2	0.0	3.3
<b>Net cash flows from investing activities</b>	<b>73.4</b>	<b>50.4</b>	<b>-23.0</b>
Cash flows from financing activities			
Net (increase) decrease in borrowings	-0.0	-	0.0
Purchase of treasury shares	-24.1	-7.3	16.8
Dividends paid	-21.2	-20.5	0.6
Other, net	-7.9	-6.8	1.1
<b>Net cash flows from financing activities</b>	<b>-53.2</b>	<b>-34.7</b>	<b>18.5</b>
<b>Net increase (decrease) in cash and cash equivalents</b>	<b>45.9</b>	<b>48.6</b>	<b>2.7</b>
<b>Cash and cash equivalents at the beginning of the period</b>	<b>189.4</b>	<b>222.2</b>	<b>32.8</b>
<b>Effect of exchange rate changes on cash and cash equivalents</b>	<b>3.1</b>	<b>-11.9</b>	<b>-15.0</b>
<b>Cash and cash equivalents at the end of the period</b>	<b>238.4</b>	<b>258.9</b>	<b>20.5</b>
* <b>Free cash flows (Cash flows from operating activities and investing activities)</b>	<b>99.1</b>	<b>83.3</b>	<b>-15.8</b>

FY2015: Increase in time deposits and securities

FY2015: Sale of Sun Pharma shares

## 6. Number of Employees

	Jun. 2015	Mar. 2016	Jun. 2016
	Results	Results	Results
Consolidated	16,460	15,249	15,306
Japan	8,619	8,589	8,762
North America	3,285	2,321	2,523
Europe	2,092	1,997	1,859
Others	2,464	2,342	2,162

## 7. Capital Expenditure and Depreciation and Amortization

	JPY Bn	FY2015 Q1	FY2015	FY2016 Q1	FY2016
		Results	Results	Results	Forecast
Capital expenditure		5.8	23.3	3.9	33.0
Depreciation and amortization		10.6	44.3	10.9	46.0
Property, plant and equipment		6.5	28.0	7.3	-
Intangible assets		4.0	16.3	3.6	-

## 8. Summary of Product Outlines

Brand Name	Generic Name	Therapeutic Category	Launched	Origin	Marketing Alliance	Type of Alliance
<b>Japan</b>						
Nexium	esomeprazole	ulcer treatment	2011	AstraZeneca	AstraZeneca	Co-promotion (DS: Sales)
Olmetec	olmesartan	antihypertensive agent	2004	Daiichi Sankyo		
Memary	memantine	Alzheimer's disease treatment	2011	Merz		
Loxonin			1986	Daiichi Sankyo		
Loxonin Poultice	loxoprofen	anti-inflammatory analgesic	2006	Lead Chemical		
Loxonin Tape			2008	Lead Chemical		
Loxonin Gel			2010	Daiichi Sankyo		
Tenelia	teneligliptin	type 2 diabetes mellitus inhibitor	2012	Mitsubishi Tanabe	Mitsubishi Tanabe	Co-promotion (DS: Sales)
Lixiana	edoxaban	anticoagulant agent	2011	Daiichi Sankyo		
Rezaltas	olmesartan / azelnidipine	antihypertensive agent	2010	Daiichi Sankyo		
Pralia	denosumab	treatment for osteoporosis	2013	Amgen		
Ranmark	denosumab	treatment for bone complications caused by bone metastases from tumors	2012	Amgen		
Inavir	laninamivir	anti-influenza treatment	2010	Daiichi Sankyo		
Cravit	levofloxacin	synthetic antibacterial agent	1993	Daiichi Sankyo		
Omnipaque	iohexol	contrast medium	1987	GE Healthcare		
Urief	silodosin	treatment for dysuria	2006	Kissei	Kissei	Co-marketing
Artist	carvedilol	treatment for hypertension, angina pectoris and chronic heart failure	1993	Roche		
Mevalotin	pravastatin	antihyperlipidemic agent	1989	Daiichi Sankyo		
Efient	prasugrel	antiplatelet agent	2014	Daiichi Sankyo Ube Industries		
<b>Daiichi Sankyo, Inc. (US)</b>						
Olmesartan						
Benicar	olmesartan		2002			
Benicar HCT	olmesartan / hydrochlorothiazide	antihypertensive agent	2003	Daiichi Sankyo		
Azor	olmesartan / amlodipine		2007			
Tribenzor	olmesartan / amlodipine / hydrochlorothiazide		2010			
Welchol	colesevelam	hypercholesterolemia treatment/ type 2 diabetes mellitus inhibitor	2000	Genzyme		
Effient	prasugrel	antiplatelet agent	2009	Daiichi Sankyo Ube Industries	Lilly	Co-promotion (DS: Co-pro revenue)
Savaysa	edoxaban	anticoagulant agent	2015	Daiichi Sankyo		
Movantik	naloxegol	opioid-induced constipation treatment	2015	Nektar AstraZeneca	AstraZeneca	Co-promotion (DS: Co-pro revenue)
<b>Luitpold Pharmaceuticals, Inc. (US)</b>						
Venofer	iron sucrose injection	treatment for iron deficiency anemia	2000	Vifor Pharma	Fresenius	Co-marketing
Injectafer	ferric carboxymaltose injection	treatment for iron deficiency anemia	2013	Vifor Pharma		
<b>Daiichi Sankyo Europe GmbH</b>						
Olmesartan						
Olmetec	olmesartan		2002			
Olmetec Plus	olmesartan / hydrochlorothiazide	antihypertensive agent	2005	Daiichi Sankyo	Menarini Pfizer	Co-marketing
Sevikar	olmesartan / amlodipine		2009			
Sevikar HCT	olmesartan / amlodipine / hydrochlorothiazide		2010			
Efient	prasugrel	antiplatelet agent	2009	Daiichi Sankyo Ube Industries		
Lixiana	edoxaban	anticoagulant agent	2015	Daiichi Sankyo	Merck (MSD)	Co-marketing

<9. Quarterly Data>

1. Consolidated Statement of Profit or Loss

JPY Bn	FY2015	FY2015	FY2015	FY2015	FY2015				FY2016	FY2016	FY2016	FY2016	FY2016	
	Q1	Q2	Q3	Q4	to revenue	Results	YoY	YoY (%)	Q1	Q2	Q3	Q4	to revenue	Results
	Results	Results	Results	Results					Results	Results	Results	Results		
<b>Revenue</b>	<b>238.4</b>	<b>240.4</b>	<b>279.8</b>	<b>227.9</b>	<b>100.0%</b>	<b>986.4</b>	<b>67.1</b>	<b>+7.3%</b>	<b>241.0</b>				<b>100.0%</b>	<b>241.0</b>
Cost of sales	74.0	75.0	88.8	80.9	32.3%	318.6	-4.5	-1.4%	77.6				32.2%	77.6
(excl. Special items)	76.3	76.1	88.8	74.4	32.0%	315.6	29.7	+10.4%	77.6				32.2%	77.6
(Special items)	-2.4	-1.1	-	6.5	0.3%	3.0	-34.1	-91.8%	-				-	-
Gross Profit	164.5	165.4	191.0	147.0	67.7%	667.8	71.5	+12.0%	163.4				67.8%	163.4
SG&A expenses	71.6	72.8	87.8	96.5	33.3%	328.8	-2.4	-0.7%	69.5				28.8%	69.5
(excl. Special items)	75.6	77.1	81.7	84.6	32.3%	319.0	0.3	+0.1%	69.5				28.8%	69.5
(Special items)	-3.9	-4.3	6.1	11.9	1.0%	9.8	-2.8	-22.1%	-				-	-
R&D expenses	43.7	44.7	49.8	70.5	21.2%	208.7	18.0	+9.4%	46.6				19.3%	46.6
(excl. Special items)	43.7	44.7	49.5	65.2	20.6%	203.0	16.8	+9.0%	46.6				19.3%	46.6
(Special items)	-	-	0.3	5.4	0.6%	5.6	1.2	+27.0%	-				-	-
<b>Operating Profit</b>	<b>49.1</b>	<b>47.9</b>	<b>53.4</b>	<b>-20.0</b>	<b>13.2%</b>	<b>130.4</b>	<b>56.0</b>	<b>+75.2%</b>	<b>47.3</b>				<b>19.6%</b>	<b>47.3</b>
(Operating Profit before Special items)	42.9	42.5	59.8	3.7	15.1%	148.9	20.3	+15.8%	47.3				19.6%	47.3
Financial income/expenses	-3.7	-2.1	1.0	-2.9		-7.7	-14.2		-1.9					-1.9
Share of profit or loss of investments accounted for using the equity method	-0.2	-0.1	0.2	-0.2		-0.3	0.6		-0.2					-0.2
<b>Profit before tax</b>	<b>45.2</b>	<b>45.6</b>	<b>54.6</b>	<b>-23.0</b>	<b>12.4%</b>	<b>122.4</b>	<b>42.5</b>	<b>+53.1%</b>	<b>45.2</b>				<b>18.8%</b>	<b>45.2</b>
Income taxes	11.1	10.3	14.7	5.9		42.0	5.6	+15.4%	15.1					15.1
<b>Profit for the year</b>	<b>34.1</b>	<b>35.3</b>	<b>39.9</b>	<b>-28.9</b>	<b>8.2%</b>	<b>80.4</b>	<b>36.8</b>	<b>+84.5%</b>	<b>30.1</b>				<b>12.5%</b>	<b>30.1</b>
<b>Profit attributable to owners of the Company</b>	<b>34.9</b>	<b>35.8</b>	<b>40.0</b>	<b>-28.4</b>	<b>8.3%</b>	<b>82.3</b>	<b>35.8</b>	<b>+77.1%</b>	<b>30.6</b>				<b>12.7%</b>	<b>30.6</b>
Tax rate	24.6%	22.5%	27.0%	-25.5%		34.3%			33.4%					33.4%
Overseas sales ratio	46.8%	46.2%	40.6%	41.5%		43.7%			42.0%					42.0%
<u>Currency Rate (Average)</u>														
USD/JPY	121.37	121.80	121.70	120.14		120.14			108.25					108.25
EUR/JPY	134.16	135.07	134.37	132.57		132.57			122.17					122.17

<9. Quarterly Data>

**2. Revenue of Global Products**

JPY Bn	FY2015 Q1	FY2015 Q2	FY2015 Q3	FY2015 Q4	FY2015			FY2016 Q1	FY2016 Q2	FY2016 Q3	FY2016 Q4	FY2016
	Results	Results	Results	Results	Results	YoY	YoY (%)	Results	Results	Results	Results	Results
<b>Olmesartan</b>	<b>75.6</b>	<b>71.9</b>	<b>80.9</b>	<b>55.7</b>	<b>284.1</b>	<b>-9.4</b>	<b>-3.2%</b>	<b>65.7</b>				<b>65.7</b>
Olmetec (JPN)	18.5	17.7	24.3	13.4	73.9	-2.5	-3.2%	18.3				18.3
Rezaltas (JPN)	4.6	4.3	5.2	4.1	18.2	-0.2	-1.3%	4.7				4.7
Benicar/Benicar HCT (US)	19.8	20.5	22.8	16.3	79.5	2.5	+3.2%	17.3				17.3
Azor (US)	5.8	4.6	5.2	4.1	19.7	1.5	+8.1%	3.3				3.3
Tribenzor (US)	3.1	3.2	3.3	2.8	12.4	1.1	+9.8%	2.5				2.5
Olmetec/Olmetec Plus (EU)	8.9	8.2	7.8	7.9	32.8	-4.9	-13.1%	7.7				7.7
Sevikar (EU)	4.5	4.1	3.5	4.4	16.5	-1.1	-6.3%	3.6				3.6
Sevikar HCT (EU)	2.5	2.2	2.8	2.2	9.6	-0.3	-2.7%	2.7				2.7
Other subsidiaries, export, etc	7.9	7.1	6.0	0.5	21.6	-5.4	-20.2%	5.6				5.6
<b>Prasugrel</b>	<b>7.8</b>	<b>7.4</b>	<b>8.7</b>	<b>8.2</b>	<b>32.2</b>	<b>7.3</b>	<b>+29.4%</b>	<b>10.9</b>				<b>10.9</b>
Effient alliance revenue (US)	5.2	5.4	5.8	4.3	20.7	3.2	+18.1%	6.0				6.0
Efient (EU)	1.1	1.1	1.1	2.1	5.4	0.6	+13.0%	2.3				2.3
Efient (JPN)	1.2	0.6	1.5	1.6	4.9	4.2	+613.5%	2.5				2.5
Other subsidiaries, export, etc	0.3	0.4	0.3	0.2	1.2	-0.7	-36.5%	0.2				0.2
<b>Edoxaban</b>	<b>1.8</b>	<b>3.5</b>	<b>5.2</b>	<b>4.5</b>	<b>15.0</b>	<b>10.7</b>	<b>+251.1%</b>	<b>7.3</b>				<b>7.3</b>
Lixiana (JPN)	2.1	3.2	4.2	3.4	13.0	9.4	+262.6%	5.5				5.5
Savaysa (US)	-0.3	0.1	0.5	0.2	0.4	-0.2	-35.6%	0.3				0.3
Lixiana (EU)	0.0	0.1	0.5	0.9	1.5	1.5	-	1.4				1.4
Other subsidiaries	-	-	-	0.0	0.0	0.0	-	0.1				0.1

### 3. Revenue by Business Units and Products (1)

JPY Bn	FY2015 Q1	FY2015 Q2	FY2015 Q3	FY2015 Q4	FY2015			FY2016 Q1	FY2016 Q2	FY2016 Q3	FY2016 Q4	FY2016
	Results	Results	Results	Results	Results	YoY	YoY (%)	Results	Results	Results	Results	Results
<b>Japan</b>	<b>114.2</b>	<b>113.6</b>	<b>149.6</b>	<b>117.2</b>	<b>494.7</b>	<b>14.2</b>	<b>+2.9%</b>	<b>123.4</b>				<b>123.4</b>
Nexium	19.1	19.6	23.3	20.4	82.4	13.1	+18.8%	21.0				21.0
Olmetec	18.5	17.7	24.3	13.4	73.9	-2.5	-3.2%	18.3				18.3
Memary	10.2	10.2	12.2	9.7	42.4	5.6	+15.3%	12.1				12.1
Loxonin	12.6	11.8	13.9	9.9	48.1	-1.4	-2.8%	10.3				10.3
Tenelia	2.4	3.0	6.6	4.6	16.5	9.0	+118.9%	6.7				6.7
Lixiana	2.1	3.2	4.2	3.4	13.0	9.4	+262.6%	5.5				5.5
Rezaltas	4.6	4.3	5.2	4.1	18.2	-0.2	-1.3%	4.7				4.7
Pralia	2.6	2.8	3.7	3.4	12.5	5.1	+70.1%	4.1				4.1
Ranmark	2.9	3.0	3.5	3.0	12.4	2.2	+22.0%	3.4				3.4
Inavir	0.0	0.0	2.5	11.5	14.0	-2.6	-15.4%	0.6				0.6
Cravit	4.6	4.4	5.6	3.8	18.4	-9.5	-34.0%	3.8				3.8
Omnipaque	4.2	4.2	4.8	3.6	16.9	-0.3	-1.9%	3.7				3.7
Urief	2.9	2.8	3.3	2.8	11.8	0.3	+2.8%	3.0				3.0
Artist	4.1	3.8	4.2	3.0	15.1	-3.0	-16.8%	3.1				3.1
Mevalotin	3.6	3.4	3.8	2.7	13.4	-2.7	-16.9%	2.9				2.9
Efient	1.2	0.6	1.5	1.6	4.9	4.2	+613.5%	2.5				2.5
Daiichi Sankyo Espha products	4.3	4.3	5.6	4.3	18.5	3.6	+23.9%	5.2				5.2
Vaccines business	6.4	8.0	15.6	6.8	36.8	4.6	+14.2%	6.6				6.6
<b>Daiichi Sankyo Healthcare (OTC)</b>	<b>10.8</b>	<b>13.8</b>	<b>15.2</b>	<b>13.5</b>	<b>53.4</b>	<b>5.5</b>	<b>+11.6%</b>	<b>14.8</b>				<b>14.8</b>

### 3. Revenue by Business Units and Products (2)

JPY Bn	FY2015 Q1	FY2015 Q2	FY2015 Q3	FY2015 Q4	FY2015			FY2016 Q1	FY2016 Q2	FY2016 Q3	FY2016 Q4	FY2016
	Results	Results	Results	Results	Results	YoY	YoY (%)	Results	Results	Results	Results	Results
<b>Daiichi Sankyo, Inc. (US)</b>	<b>48.0</b>	<b>45.4</b>	<b>52.1</b>	<b>39.6</b>	<b>185.1</b>	<b>12.1</b>	<b>+7.0%</b>	<b>40.7</b>				<b>40.7</b>
Olmesartan	28.8	28.3	31.3	23.2	111.6	5.1	+4.7%	23.2				23.2
Benicar/Benicar HCT	19.8	20.5	22.8	16.3	79.5	2.5	+3.2%	17.3				17.3
Azor	5.8	4.6	5.2	4.1	19.7	1.5	+8.1%	3.3				3.3
Tribenzor	3.1	3.2	3.3	2.8	12.4	1.1	+9.8%	2.5				2.5
Welchol	13.5	10.6	13.5	10.7	48.4	1.0	+2.1%	10.0				10.0
Effient	5.2	5.4	5.8	4.3	20.7	3.2	+18.1%	6.0				6.0
Savaysa	-0.3	0.1	0.5	0.2	0.4	-0.2	-35.6%	0.3				0.3
Movantik	0.2	0.4	0.7	0.7	2.0	2.0	-	0.9				0.9
<b>Luitpold Pharmaceuticals, Inc. (US)</b>	<b>21.5</b>	<b>24.9</b>	<b>22.6</b>	<b>22.0</b>	<b>91.0</b>	<b>33.6</b>	<b>+58.6%</b>	<b>22.0</b>				<b>22.0</b>
Venofer	9.1	6.9	8.4	6.8	31.2	2.6	+9.2%	7.4				7.4
Injectafer	3.9	4.0	5.0	5.8	18.6	11.0	+143.9%	5.9				5.9
<b>Daiichi Sankyo Europe GmbH</b>	<b>20.2</b>	<b>19.0</b>	<b>18.8</b>	<b>19.7</b>	<b>77.8</b>	<b>-5.7</b>	<b>-6.9%</b>	<b>20.4</b>				<b>20.4</b>
Olmesartan	15.8	14.4	14.2	14.5	58.9	-6.3	-9.7%	14.0				14.0
Olmetec/Olmetec Plus	8.9	8.2	7.8	7.9	32.8	-4.9	-13.1%	7.7				7.7
Sevikar	4.5	4.1	3.5	4.4	16.5	-1.1	-6.3%	3.6				3.6
Sevikar HCT	2.5	2.2	2.8	2.2	9.6	-0.3	-2.7%	2.7				2.7
Efient	1.1	1.1	1.1	2.1	5.4	0.6	+13.0%	2.3				2.3
Lixiana	0.0	0.1	0.5	0.9	1.5	1.5	-	1.4				1.4
<b>Asia, South and Central America (ASCA)</b>	<b>21.4</b>	<b>21.3</b>	<b>19.9</b>	<b>12.7</b>	<b>75.3</b>	<b>7.8</b>	<b>+11.6%</b>	<b>17.7</b>				<b>17.7</b>
Daiichi Sankyo China	7.9	8.6	8.3	9.4	34.2	6.9	+25.1%	8.2				8.2
Daiichi Sankyo Taiwan	1.4	1.3	1.3	1.4	5.4	0.5	+10.5%	1.3				1.3
Daiichi Sankyo Korea	2.4	2.4	2.4	2.2	9.3	0.5	+5.2%	2.1				2.1
Daiichi Sankyo Thailand	0.8	1.0	1.1	1.2	4.1	0.4	+11.5%	0.6				0.6
Daiichi Sankyo Brasil Farmacêutica	2.6	1.9	2.1	1.4	8.1	-0.3	-3.1%	2.0				2.0
Daiichi Sankyo Venezuela	3.1	2.4	1.6	-6.9	0.2	-7.9	-98.0%	0.0				0.0



### 3. Revenue by Business Units and Products (3)

#### [Reference] Revenue in Local Currency

	FY2015 Q1	FY2015 Q2	FY2015 Q3	FY2015 Q4	FY2015			FY2016 Q1	FY2016 Q2	FY2016 Q3	FY2016 Q4	FY2016
	Results	Results	Results	Results	Results	YoY	YoY (%)	Results	Results	Results	Results	Results
USD Mn												
<b>Daiichi Sankyo, Inc. (US)</b>	<b>396</b>	<b>371</b>	<b>429</b>	<b>345</b>	<b>1,540</b>	<b>-33</b>	<b>-2.1%</b>	<b>376</b>				<b>376</b>
Olmesartan	237	232	257	202	929	-40	-4.2%	214				214
Benicar/Benicar HCT	163	168	187	143	661	-39	-5.6%	160				160
Azor	48	38	43	35	164	-2	-1.1%	31				31
Tribenzor	26	26	27	24	103	1	+0.5%	23				23
Welchol	112	87	111	93	403	-29	-6.6%	92				92
Effient	43	44	48	38	173	13	+8.0%	55				55
Savaysa	-2	1	4	1	4	-3	-41.1%	3				3
Movantik	1	3	6	6	17	17	-	8				8
USD Mn												
<b>Luitpold Pharmaceuticals, Inc. (US)</b>	<b>177</b>	<b>204</b>	<b>186</b>	<b>191</b>	<b>758</b>	<b>236</b>	<b>+45.2%</b>	<b>203</b>				<b>203</b>
Venofer	75	57	69	59	260	-0	-0.1%	68				68
Injectafer	32	33	41	49	155	86	+123.2%	55				55
EUR Mn												
<b>Daiichi Sankyo Europe GmbH</b>	<b>151</b>	<b>140</b>	<b>142</b>	<b>155</b>	<b>587</b>	<b>-15</b>	<b>-2.5%</b>	<b>167</b>				<b>167</b>
Olmesartan	118	106	106	114	444	-25	-5.4%	114				114
Olmetec/Olmetec Plus	66	60	59	62	248	-24	-9.0%	63				63
Sevikar	33	30	27	34	124	-2	-1.9%	29				29
Sevikar HCT	18	16	21	17	73	1	+1.9%	22				22
Efient	8	8	8	16	41	6	+18.3%	19				19
Lixiana	0	1	4	7	12	12	-	12				12

## <10. Historical Data>

### 1. Revenue of Global Products

	FY2011	FY2012	FY2013	FY2014	FY2015
JPY Bn	Results	Results	Results	Results	Results
<b>Olmesartan</b>	<b>249.7</b>	<b>258.9</b>	<b>300.2</b>	<b>293.5</b>	<b>284.1</b>
Olmetec (JPN)	80.9	78.3	79.1	76.3	73.9
Rezaltas (JPN)	13.5	16.9	18.5	18.4	18.2
Benicar/Benicar HCT (US)	71.3	73.2	85.9	77.0	79.5
Azor (US)	12.0	14.8	17.4	18.3	19.7
Tribenzor (US)	4.6	6.8	9.0	11.3	12.4
Olmetec/Olmetec Plus (EU)	36.6	32.6	44.5	37.8	32.8
Sevikar (EU)	11.0	10.8	13.5	17.6	16.5
Sevikar HCT (EU)	3.4	4.7	7.6	9.9	9.6
Other subsidiaries, export, etc	16.5	20.7	24.7	27.0	21.6
<b>Prasugrel</b>	<b>10.9</b>	<b>14.4</b>	<b>22.3</b>	<b>24.9</b>	<b>32.2</b>
Effient alliance revenue (US)	7.9	10.5	15.4	17.6	20.7
Efient (EU)	2.9	3.9	4.7	4.8	5.4
Efient (JPN)	-	-	-	0.7	4.9
Other subsidiaries, export, etc	-	-	2.2	1.9	1.2
<b>Edoxaban</b>	<b>-</b>	<b>-</b>	<b>0.4</b>	<b>4.3</b>	<b>15.0</b>
Lixiana (JPN)	-	-	0.4	3.6	13.0
Savaysa (US)	-	-	-	0.7	0.4
Lixiana (EU)	-	-	-	-	1.5
Other subsidiaries	-	-	-	-	0.0

**2. Revenue by Business Units and Products (1)**

	FY2011	FY2012	FY2013	FY2014	FY2015
JPY Bn	Results	Results	Results	Results	Results
<b>Japan</b>	<b>409.8</b>	<b>442.5</b>	<b>486.0</b>	<b>480.5</b>	<b>494.7</b>
Nexium	3.9	21.6	54.2	69.3	82.4
Olmetec	80.9	78.3	79.1	76.3	73.9
Memary	9.8	23.8	33.3	36.8	42.4
Loxonin	61.0	59.6	59.3	49.5	48.1
Tenelia	-	1.3	1.5	7.6	16.5
Lixiana	0.3	0.3	0.4	3.6	13.0
Rezaltas	13.5	16.9	18.5	18.4	18.2
Pralia	-	-	3.2	7.3	12.5
Ranmark	-	4.4	8.1	10.2	12.4
Inavir	10.7	11.1	13.4	16.6	14.0
Cravit	36.3	35.9	33.5	27.8	18.4
Omnipaque	23.5	20.2	19.7	17.2	16.9
Urief	11.0	11.1	11.4	11.5	11.8
Artist	24.5	22.4	22.4	18.1	15.1
Mevalotin	33.1	25.8	21.5	16.2	13.4
Efient	-	-	-	0.7	4.9
Daiichi Sankyo Espha products	9.9	11.1	12.5	14.9	18.5
Vaccines business	21.2	39.1	37.5	32.2	36.8
<b>Daiichi Sankyo Healthcare (OTC)</b>	<b>45.9</b>	<b>47.1</b>	<b>48.1</b>	<b>47.8</b>	<b>53.4</b>

## 2. Revenue by Business Units and Products (2)

	FY2011	FY2012	FY2013	FY2014	FY2015
JPY Bn	Results	Results	Results	Results	Results
<b>Daiichi Sankyo, Inc. (US)</b>	<b>127.1</b>	<b>142.3</b>	<b>171.8</b>	<b>173.0</b>	<b>185.1</b>
Olmesartan	87.9	94.9	112.3	106.6	111.6
Benicar/Benicar HCT	71.3	73.2	85.9	77.0	79.5
Azor	12.0	14.8	17.4	18.3	19.7
Tribenzor	4.6	6.8	9.0	11.3	12.4
Welchol	26.9	33.1	42.3	47.4	48.4
Effient	7.9	10.5	15.4	17.6	20.7
Savaysa	-	-	-	0.7	0.4
Movantik	-	-	-	-	2.0
<b>Luitpold Pharmaceuticals, Inc. (US)</b>	<b>44.7</b>	<b>38.6</b>	<b>39.6</b>	<b>57.4</b>	<b>91.0</b>
Venofer	24.8	23.6	24.9	28.6	31.2
Injectafer	-	-	1.3	7.6	18.6
<b>Daiichi Sankyo Europe GmbH</b>	<b>70.2</b>	<b>64.4</b>	<b>83.9</b>	<b>83.5</b>	<b>77.8</b>
Olmesartan	51.0	48.0	65.6	65.2	58.9
Olmetec/Olmetec Plus	36.6	32.6	44.5	37.8	32.8
Sevikar	11.0	10.8	13.5	17.6	16.5
Sevikar HCT	3.4	4.7	7.6	9.9	9.6
Efient	2.9	3.9	4.7	4.8	5.4
Lixiana	-	-	-	-	1.5
<b>Asia, South and Central America (ASCA)</b>	<b>28.6</b>	<b>45.4</b>	<b>58.8</b>	<b>67.5</b>	<b>75.3</b>
Daiichi Sankyo China	9.7	16.4	21.2	27.4	34.2
Daiichi Sankyo Taiwan	3.1	3.3	4.5	4.9	5.4
Daiichi Sankyo Korea	4.6	5.3	9.1	8.9	9.3
Daiichi Sankyo Thailand	1.2	1.4	2.5	3.7	4.1
Daiichi Sankyo Brasil Farmacêutica	5.5	6.6	7.5	8.4	8.1
Daiichi Sankyo Venezuela	4.2	6.7	6.9	8.1	0.2

**2. Revenue by Business Units and Products (3)****[Reference] Revenue in Local Currency**

	FY2011	FY2012	FY2013	FY2014	FY2015
	Results	Results	Results	Results	Results
USD Mn					
<b>Daichi Sankyo, Inc. (US)</b>	<b>1,608</b>	<b>1,713</b>	<b>1,714</b>	<b>1,574</b>	<b>1,540</b>
Olmesartan	1,112	1,142	1,120	969	929
Benicar/Benicar HCT	901	881	857	700	661
Azor	152	179	174	166	164
Tribenzor	58	82	90	103	103
Welchol	340	399	422	431	403
Effient	100	127	154	160	173
Savaysa	-	-	-	6	4
Movantik	-	-	-	-	17
USD Mn					
<b>Luitpold Pharmaceuticals, Inc. (US)</b>	<b>566</b>	<b>465</b>	<b>395</b>	<b>522</b>	<b>758</b>
Venofer	314	284	248	260	260
Injectafer	-	-	13	69	155
EUR Mn					
<b>Daichi Sankyo Europe GmbH</b>	<b>644</b>	<b>601</b>	<b>624</b>	<b>602</b>	<b>587</b>
Olmesartan	468	448	488	470	444
Olmetec/Olmetec Plus	336	304	331	272	248
Sevikar	101	100	100	127	124
Sevikar HCT	31	44	57	71	73
Efient	27	36	35	34	41
Lixiana	-	-	-	-	12

11. Major R&D Pipeline (Innovative pharmaceuticals)

As of July 2016

◆ Launched/Approved

Generic Name	Class	Indication	Region Status	Remarks
Edoxaban	Factor Xa inhibitor	Atrial fibrillation (AF)	ASCA etc. Approved	Taiwan (16/2), Hong Kong (16/5) * means Feb 2016, ditto
		Venous thromboembolism (VTE)	ASCA etc. Approved	Taiwan (16/2), Hong Kong (16/5)
<Summary> The once daily oral anti coagulant (FXa inhibitor) discovered by Daiichi Sankyo. Edoxaban specifically, reversibly and directly inhibits the enzyme, Factor Xa, a clotting factor in the blood. Launched in Japan in July 2011 as the prevention of venous thromboembolism (VTE) in patients with total knee arthroplasty, total hip arthroplasty and hip fracture surgery. Additional indications for AF/VTE was approved in September 2014 and 60 mg tablet was launched in December 2014. Launched in US, Switzerland, UK, Germany, Ireland and Netherlands in February, May, July, August, September and November 2015, respectively. Approved in South Korea in August 2015. Underline: change after FY2015 Q4 Financial Announcement in May 2016				

◆ Filed

Product Code Number/Generic Name	Class	Target indication	Region	Note, Filing year/month
Edoxaban	Factor Xa inhibitor	Atrial fibrillation (AF)	ASCA etc.	BR (14/6), TH(15/7) AU(15/8), CN(15/8), CA(15/8), TR(15/10)
		Venous thromboembolism (VTE)	ASCA etc.	BR (14/6), TH(15/7) AU(15/8), CN(15/8), CA(15/8), TR(15/10)
<Summary> The once daily oral anti coagulant (FXa inhibitor) discovered by Daiichi Sankyo. Edoxaban specifically, reversibly and directly inhibits the enzyme, Factor Xa, a clotting factor in the blood.				
CL-108	Opioid mu-receptor agonist combination	Acute pain	US	NDA was submitted in March 2016 by Charleston Laboratories, Inc., licensor and co-development partner
<Summary> CL-108 is novel hydrocodone combination products being developed by Charleston Lab and Daiichi Sankyo for the treatment of moderate to severe pain while preventing or reducing Opioid-Induced Nausea and Vomiting (OINV). The product expects to reduce the unwanted side effects of opioid-induced nausea and vomiting.				
Hydromorphone	Opioid mu-receptor agonist	Cancer pain	JP	NDA of oral formulation (extended-release and immediate-release formulations) was submitted in March 2016 by Daiichi Sankyo Propharma
<Summary> Hydromorphone hydrochloride is an opiate, narcotic analgesic that has been available outside of Japan for over 80 years and it is the standard for pain management for cancer pain treatment according to WHO guidelines. Hydromorphone hydrochloride is one of the agents publicly offered for development by the Review Committee on Unapproved Drugs and Indications with High Medical Needs. Daiichi Sankyo decided to develop the drug in 2012.				
VN-100	Intradermal influenza HA vaccine	Prevention of seasonal Influenza	JP	Submitted by Japan Vaccine in April 2015
<Summary> The Vaccine is a pre-filled syringe type, intradermal influenza HA vaccine co-developed by four companies [Daiichi Sankyo, Terumo, Japan Vaccine and Kitasato Daiichi Sankyo Vaccine Co., Ltd.]. The intradermal injection device for this vaccine is developed by Terumo. This device, which offers a more easy-to-use, surefire method to administer the vaccine than current methods. The device is also expected to ease patient hesitation to be injected and lower the risk of damaging peripheral blood vessels and nerves within the subcutaneous tissue.				
VN-0107/MEDI3250	Live attenuated influenza vaccine	Prevention of seasonal Influenza	JP	Submitted by Daiichi Sankyo in June 2016
<Summary> The US brand name of this vaccine is FluMist Quadrivalent that is a live attenuated influenza vaccine which is administered as a nasal spray and contains four protective strains.				

Underline: change after FY2015 Q4 Financial Announcement in May 2016

◆ Under development (Phase1-3)

Generic Name / Project Code Number	Class	Target indication	Stage		target FY for approval/launch basically for P3	Remarks
Prasugrel	Anti-platelet agent	Ischemic stroke	JP	P3	2017	Additional indication
Denosumab	Anti-RANKL antibody	Breast cancer adjuvant	JP	P3	2020	Additional indication
		Rheumatoid arthritis	JP	P3	2017	Additional indication
Tivantinib	MET inhibitor	Hepatocellular cancer	US/EU	P3	2018	
Nimotuzumab	Anti-EGFR antibody	Gastric cancer	JP	P3	2020	
Vemurafenib	BRAF inhibitor	Melanoma adjuvant	US/EU	P3	-	Additional indication. Licensee Roche is conducting the study. Submission in 2016 is planned.
Quizartinib	FLT3-ITD inhibitor	Acute myeloid leukemia	US/EU/Asia	P3	2018	Relapsed and refractory AML patients
			US	P3	2021-	Newly diagnosed AML patients
			JP	P1	-	
Pexidartinib/PLX3397	CSF-1R/KIT/FLT3-ITD inhibitor	Tenosynovial Giant Cell Tumor (TGCT)	US/EU	P3	2019	Including pigmented villonodular synovitis
		<u>Solid tumor</u>	Asia	P1	-	<u>Including TGCT</u>
		Glioblastoma	US	P2	-	
		Melanoma	US	P2	-	
		Melanoma, solid tumor	US	P1/2	-	Combination with pembrolizumab in collaboration with Merck
Mirogabalin	α2δ ligand	Fibromyalgia	US/EU	P3	2019	
		Diabetic peripheral neuropathic pain	JP/Asia	P3	2018	
		Postherpetic neuralgia	JP/Asia	P3	2018	
Hydromorphone	Opioid mu-receptor agonist	Cancer pain	JP	P3	2018	Injection formulation
CHS-0214	TNFα inhibitor	Rheumatoid arthritis	JP	P3	2017	Etanercept biosimilar
VN-0105	DPT-IPV/Hib vaccine	Prevention of pertussis, diphtheria, tetanus, poliomyelitis and Hib	JP	P3	2019	Co-develop with Sanofi K.K.and KDSV
Patritumab	Anti-HER3 antibody	Head & neck cancer	EU	P2	-	
<u>DS-1647</u>	<u>G47 Δ oncolytic virus</u>	<u>Glioblastoma</u>	<u>JP</u>	<u>P2</u>	-	<u>SAKIGAKE Designation granted</u>
CS-3150	MR antagonist	Hypertension	JP	P2b	-	
		Diabetic nephropathy	JP	P2b	-	
DS-8500	GPR119 agonist	Diabetes	JP/US	P2	-	
Laninamivir	Neuraminidase inhibitor	Influenza	US/EU	P2	-	Out-licensing with Biota
			JP	P1	-	Nebulizer formulation

Underline: change after FY2015 Q4 Financial Announcement in May 2016.

Note: regarding patritumab, breast cancer has been removed from the list because IIS is the only program for breast cancer indication.

◆ Under development (Phase1-3)

Generic Name / Project code number	Class	Target indication	Stage		target FY for approval/launch basically for P3	Remarks
DS-3032	MDM2 inhibitor	Solid cancer, lymphoma	US/JP	P1	-	
		Leukemia	US	P1	-	
PLX7486	FMS/TRK inhibitor	Solid cancer	US	P1	-	
DS-8895	Anti-EPHA2 antibody	Solid cancer	JP	P1	-	
DS-8273	Anti-DR5 antibody	Solid cancer	US	P1	-	
PLX8394	BRAF inhibitor	Solid cancer, leukemia	US	P1	-	
DS-6051	NTRK/ROS1 inhibitor	Solid cancer	US/JP	P1	-	
DS-5573	Anti-B7-H3 antibody	Solid cancer	JP	P1	-	
PLX9486	KIT inhibitor	Solid cancer	US	P1	-	
DS-8201	Anti-HER2 antibody drug conjugate	Solid cancer	JP	P1	-	
U3-1784	Anti-FGFR4 antibody	Solid cancer	EU	P1	-	
DS-1123	Anti-FGFR2 antibody	Solid cancer	JP	P1	-	
DS-3201	EZH1/2 inhibitor	Non-Hodgkin's lymphoma	JP	P1	-	
PLX73086/AC708	CSF-1R inhibitor	Tenosynovial Giant Cell Tumor (TGCT)	US	P1	-	
PLX51107	BRD4 inhibitor	Hematologic malignancies	US	P1	-	
DS-1040	TAF1a inhibitor	Acute ischemic stroke	-	P1	-	
DS-2330	Hyperphosphatemia treatment	Hyperphosphatemia in chronic kidney disease (CKD)	-	P1	-	
DS-9231/TS23	α2 plasmin inhibitor-inactivating antibody	Thrombosis (cardiovascular diseases, ischemic stroke)	-	P1	-	In-licensed from Translational Sciences Inc.
DS-9001	Anti-PCSK9 Anticalin-Albumod	Dyslipidemia	-	P1	-	
DS-1971	Analgesic agent	Chronic pain	-	P1	-	
DS-1501	Anti-Siglec-15 antibody	Osteoporosis	US	P1	-	
DS-7080	Angiogenesis inhibitor	Neovascular age-related macular degeneration (AMD)	US	P1	-	
DS-2969	GyrB inhibitor	Clostridium difficile infection (CDI)	-	P1	-	
DS-5141	ENA oligonucleotide	Duchenne muscular dystrophy	JP	P1/2	-	
VN-0102/JVC-001	Measles-Mumps-Rubella vaccine	Prevention of Measles, Mumps and Rubella	JP	P1/2	2020	Japan vaccine company is conducting the phase 1/2 study

◆ Stage-up (major changes from the FY2015 Q4 Financial Announcement in May 2016)

Generic Name / Project code number	Class	Target indication	Current stage		Remarks
Edoxaban	FXa inhibitor	Atrial Fibrillation (AF) Venous thromboembolism (VTE)	ASCA etc.	Approved	Hong Kong (16/5)
VN-0107/MEDI3250	Live attenuated influenza vaccine	Prevention of seasonal influenza	JP	Submitted	Submitted by Daiichi Sankyo in June 2016
Pexidartinib/PLX3397	CSF-1R/KIT/FLT3-ITD inhibitor	Solid tumor	Asia	P1	Including TGCT
DS-1647	G47Δ oncolytic virus	Glioblastoma	JP	P2	SAKIGAKE Designation granted

◆ Discontinue (major changes from the FY2015 Q4 Financial Announcement in May 2016)

Generic Name / Project code number	Class	Target indication	Stage	
Patritumab	Anti-HER3 antibody	Non small cell lung cancer	US/EU	P2
			JP	P1
<Reason> Daiichi Sankyo decided to discontinue the development after reviewing its study results.				



## Oncology

[ Project after Phase 2 ]

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Tivantinib	ARQ 197	Oral	MET inhibitor	- Hepatocellular cancer	ArQule	TBD

<Summary>

The molecular-targeted agent to inhibit HGF(hepatocyte growth factor) receptor, MET which has multiple roles in intracellular signal transductions such as cancer cell proliferation, angiogenesis, invasion, and apoptosis induction.

• A P3 clinical study for HCC with MET high patients was started in Jan 2013.

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Nimotuzumab	DE-766	Injection	Anti-EGFR antibody	- Gastric cancer	InnoCIMAAb	TBD

<Summary>

The humanized monoclonal antibody to target Epidermal Growth Factor Receptor(EGFR). This antibody is expected to be a best in class EGFR, safety against the skin toxicity and the efficacy comparable to the other antibodies.

• P3 in Japan for Gastric cancer started in April 2013.

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Quizartinib	AC220	Oral	FLT3-ITD inhibitor	- Acute myeloid leukemia	Daiichi Sankyo (Ambit)	TBD

<Summary>

Kinase inhibitor against a receptor-type tyrosine kinase, FLT3. Therapeutic effect for patients with acute myeloid leukemia harboring FLT3-ITD mutation is expected.

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Patritumab	U3-1287	Injection	Anti-HER3 antibody	- Head and neck cancer	Daiichi Sankyo (U3 Pharma)	TBD

<Summary>

The fully human monoclonal antibody to target HER3, one of the Epidermal Growth Factor Receptor (EGFR) family of proteins. HER 3 is overexpressed in many tumors of epithelial origin and HER2/HER3 dimers and EGFR/HER3 dimers are more potent to induce tumor cell proliferation than homodimers of HER2 or EGFR.

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Vemurafenib	PLX4032	Oral	BRAF inhibitor	- Melanoma adjuvant	Daiichi Sankyo (Plexxikon)	Zelboraf

<Summary>

The molecular-targeted agent to inhibit BRAF V600E mutation. Launched since 2011 as personalized treatment for patients with unresectable or metastatic melanoma. NDA for combination therapy with MEK inhibitor cobimetinib was approved in US on November 11, 2015. A Phase 1 study of a combination with anti PD-L1 monoclonal antibody atezolizumab and cobimetinib is being investigated by Genentech.

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Pexidartinib	PLX3397	Oral	CSF-1R/KIT/FLT3-ITD inhibitor	- Tenosynovial Giant Cell Tumor - Glioblastoma - Melanoma	Daiichi Sankyo (Plexxikon)	TBD

<Summary>

The molecular-targeted agent to inhibit CSF-1R, KIT and FLT3-ITD. This agent is expected to reduce tumor cell proliferation and expansion of metastases.

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
G47Δ	DS-1647	Injection	Oncolytic Virus	- Glioblastoma	Prof. Todo Institute of Medical Science Univ. of Tokyo	TBD

<Summary>

A triple-mutated, replication-conditional herpes simplex virus type 1 (the third generation oncolytic herpes simplex virus type 1), designed to replicate only in cancer cells. This oncolytic virus therapy is expected better safety and efficacy profile compare to existing oncolytic virus. This product received SAKIGAKE Designation from MHLW on February 10th ,2016. Phase 2 Investigator Initiated Study for Glioblastoma is on-going in Japan.

## Cardiovascular-Metabolics

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Edoxaban	DU-176b	Oral	Factor Xa inhibitor	- Atrial fibrillation (AF) - Venous thromboembolism (VTE)	Daiichi Sankyo	Lixiana (JP) LIXIANA (EU) SAVAYSA (US)
<p>&lt;Summary&gt; The once daily oral anti coagulant (FXa inhibitor). Edoxaban specifically, reversibly and directly inhibits the enzyme, Factor Xa, a clotting factor in the blood. Launched in Japan in July 2011 as the prevention of venous thromboembolism (VTE) in patients with total knee arthroplasty, total hip arthroplasty and hip fracture surgery.</p> <ul style="list-style-type: none"> <li>• Top line results of Hokusai-VTE (VTE) P3 study was presented at ESC 2013.</li> <li>• Top line results of ENGAGE AF-TIMI 48 (AF) P3 study was presented at AHA 2013.</li> <li>• AF/VTE indication: Launched (JP: Sep 2014 (Dec 2014 for 60 mg tablet), US: Feb 2015, Switzerland: May 2015, UK: Jul 2015, Germany: Aug 2015, Ireland: Sep 2015, Netherlands: Nov 2015, South Korea: Feb 2016)</li> </ul>						

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Prasugrel	CS-747	Oral	Anti-platelet agent	- Ischemic stroke	Daiichi Sankyo Ube Industries	Effient (US, Asia) Efiect (JPN, EU)
<p>&lt;Summary&gt; The oral antiplatelet agent. Prasugrel helps to keep blood platelets from clumping together and developing a blockage in an artery.</p> <ul style="list-style-type: none"> <li>• Co-development with Eli Lilly in the US and EU, development by Daiichi Sankyo in Japan.</li> <li>• [JP] Approved in Mar 2014 for the ischemic heart disease undergoing PCI and launched in May 2014. P3 studies for ischemic stroke are on-going.</li> <li>• [US] P3 study in pediatric sickle cell disease patients was conducted. The patent exclusivity in US has been extended for 180 days based on the pediatric study completion.</li> </ul>						

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
-	CS-3150	Oral	MR antagonist	- Hypertension - Diabetic nephropathy	Exelixis	TBD
<p>&lt;Summary&gt; The agent inhibits aldosterone binding to Mineralocorticoid Receptor(MR) which stimulate the sodium absorption into kidney. This agent is expected antihypertensive and organ-protective effect.</p> <ul style="list-style-type: none"> <li>• On January 2015, Ph2bs of HTN and DN started.</li> <li>• On November 2015, Ph.2b study in essential hypertension in Japan was completed.</li> </ul>						

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
-	DS-8500	Oral	GPR119 agonist	- Diabetes	Daiichi Sankyo	TBD
<p>&lt;Summary&gt; The agent agonistically acts on GPR119 which is expressed in small intestine and spleen cells, stimulates insulin secretion, and lowers blood sugar concentration.</p>						

## Others

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Intradermal Seasonal Influenza Vaccine	VN-100	Injection (prefilled syringe)	Seasonal flu vaccine	- Prevention of seasonal influenza	Daiichi Sankyo (KDSV) Terumo	TBD
<p>&lt;Summary&gt;            The Vaccine is a pre-filled syringe type, intradermal influenza HA vaccine co-developed by four companies [Daiichi Sankyo, Terumo, Japan Vaccine and Kitasato Daiichi Sankyo Vaccine Co., Ltd.]. The intradermal injection device for this vaccine is developed by Terumo. This device, which offers a more easy-to-use, surefire method to administer the vaccine than current methods. The device is also expected to ease patient hesitation to be injected and lower the risk of damaging peripheral blood vessels and nerves within the subcutaneous tissue.</p> <ul style="list-style-type: none"> <li>• NDA submission in Apr 2014 by Japan Vaccine</li> </ul>						

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Hydromorphone	DS-7113	Oral/ Injection	opioid mu-receptor regulator	- Cancer pain	-	TBD
<p>&lt;Summary&gt;            The opiate, narcotic analgesic that has been available outside of Japan for over 80 years and recommended in WHO guideline as a standard analgesia for cancer pain. It is designated as unapproved drug by "Study Group on Unapproved and Off-label Drugs of High Medical Need."</p> <ul style="list-style-type: none"> <li>• NDA of oral formulations (extended-release and immediate-release formulations) were submitted in Mar 2016 by Daiichi Sankyo Propharma. Ph2/3 studies for injection formulation are ongoing.</li> </ul>						

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Denosumab	AMG 162	Injection	Anti-RANKL antibody	- Breast cancer adjuvant - Rheumatoid arthritis	Amgen	SRE, GCTB: Ranmark(JP) Osteoporosis: Pralia(JP)
<p>&lt;Summary&gt;            The fully human monoclonal antibody to target RANK Ligand, an essential mediator of osteoclast formation. Launched in Japan in April 2012 as treatment for bone complications stemming from multiple myeloma and bone metastases from solid tumors, in June 2013 as treatment for osteoporosis, and in May 2014 as treatment for giant cell tumor of bone.</p> <ul style="list-style-type: none"> <li>• July 2007 In-licensed from Amgen.</li> <li>• P3 : Breast cancer adjuvant, Rheumatoid arthritis.</li> </ul>						

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
-	CHS-0214	Injection	TNF $\alpha$ inhibitor	- Rheumatoid arthritis	Coherus	TBD
<p>&lt;Summary&gt;            Biosimilar product for etanercept</p> <ul style="list-style-type: none"> <li>• Phase 3 study for patients with rheumatoid arthritis in Japan was completed. In preparation for submission.</li> </ul>						

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
-	CL-108	Oral	opioid mu-receptor regulator	- Acute pain	Charleston Laboratories	TBD
<p>&lt;Summary&gt;            Combination product of immediate-release promethazine, hydrocodone and acetaminophen. Reduction of Opioid-Induced Nausea and Vomiting is expected.            NDA submission in Mar 2016 by Charleston Laboratories</p>						

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Mirogabalin	DS-5565	Oral	$\alpha 2\delta$ ligand	- Fibromyalgia - Diabetic peripheral neuropathic pain - Postherpetic neuralgia	Daiichi Sankyo	TBD
<p>&lt;Summary&gt;            The pain therapy agent to reduce the neurotransmitter release from nerve terminals. This agent is expected to show the good balanced efficacy and safety profile.</p> <ul style="list-style-type: none"> <li>• Ph2 studies for diabetic peripheral neuropathic pain were completed.</li> <li>• Ph3 studies for diabetic peripheral neuropathic pain and postherpetic neuralgia are in execution.</li> <li>• Ph3 studies for fibromyalgia are in execution.</li> </ul>						

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
-	VN-0107 MEDI3250	Nasal spray	Seasonal flu vaccine	- Prevention of seasonal influenza	AZ/MedImmune	TBD
<p>&lt;Summary&gt;            The US brand name of this vaccine is FluMist Quadrivalent that is a live attenuated influenza vaccine which is administered as a nasal spray and contains four protective strains. Phase III safety and efficacy studies were conducted for FluMist Quadrivalent in Japanese children over the 2014-2015 influenza season and a regulatory submission is being prepared in Japan.</p> <ul style="list-style-type: none"> <li>• NDA submission in Japan in June 2016</li> </ul>						

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
-	VN-0105	Injection	DPT-IPV/Hib vaccine	- Prevention of pertussis, diphtheria, tetanus, poliomyelitis and Hib	Daiichi Sankyo (KDSV) Sanofi Pasteur	TBD
<p>&lt;Summary&gt;            A combination vaccine reconstituting Hib with precipitated and purified pertussis-diphtheria-tetanus-inactivated polio vaccine (Salk vaccine) vaccine previously licensed and launched in Japan, as 1st in the class of pentavalent vaccine (DPT-IPV/Hib).</p> <ul style="list-style-type: none"> <li>• Ph3 study in Japan started in Oct 2014.</li> </ul>						

